Trexall

Polymyositis, Uveitis, Prophylaxis against graft versus host disease + 27 more

Treatment

20 Active Studies for Trexall

What is Trexall

Methotrexate

The Generic name of this drug

Treatment Summary

Methotrexate is a type of drug that stops the body from making certain enzymes that help with cell growth and inflammation. It is used to treat arthritis, breast cancer, and non-Hodgkin's lymphoma. It is only prescribed if other treatments have not worked or if the patient cannot tolerate those treatments. Methotrexate was approved by the FDA in 1953.

Methotrexate

is the brand name

image of different drug pills on a surface

Trexall Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Methotrexate

Methotrexate

1953

137

Effectiveness

How Trexall Affects Patients

Methotrexate stops cells from dividing and reduces inflammation. It usually needs to be taken once a week and has a small margin of safety. Do not take methotrexate on a daily basis.

How Trexall works in the body

Methotrexate targets the enzymes that help cells reproduce, preventing them from dividing. In rheumatoid arthritis, methotrexate polyglutamates specifically inhibit an enzyme called AICART. This leads to a build-up of adenosine triphosphate and adenosine in the area around the cells, which helps reduce inflammation.

When to interrupt dosage

The amount of Trexall is contingent upon the diagnosed condition, including Uveitis, Polymyositis and nonleukemic meningeal cancer. The degree of dosage likewise differs according to the method of delivery featured in the table beneath.

Condition

Dosage

Administration

Takayasu Arteritis

25.0 mg/mL, , 2.5 mg, 100.0 mg/mL, 25.0 mg, 7.5 mg, 10.0 mg, 15.0 mg, 20.0 mg, 50.0 mg, 150.0 mg/mL, 200.0 mg/mL, 250.0 mg/mL, 75.0 mg/mL, 125.0 mg/mL, 225.0 mg/mL, 175.0 mg/mL, 12.5 mg, 17.5 mg, 22.5 mg, 5.0 mg, 1000.0 mg, 2.5 mg/mL, 275.0 mg/mL, 300.0 mg/mL, 10.0 mg/mL, 20.0 mg/mL, 15.0 mg/mL, 2.0 mg/mL

, Injection, Injection - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Injection, solution, Injection, solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Intra-arterial; Intramuscular; Intrathecal; Intravenous, Oral, Tablet - Oral, Tablet, Intra-arterial; Intramuscular; Intravenous, Injection, solution - Intra-arterial; Intramuscular; Intravenous, Intravenous, Intramuscular; Intrathecal; Intravenous, Powder, for solution - Intramuscular; Intrathecal; Intravenous, Liquid, Liquid - Intramuscular; Intrathecal; Intravenous, Solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous; Intraventricular, Powder, for solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Injection, solution - Subcutaneous, Subcutaneous, Tablet, film coated, Tablet, film coated - Oral, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Solution - Oral, Solution - Intravenous, Intra-arterial; Intramuscular; Intrathecal; Iontophoresis, Injection, solution - Intra-arterial; Intramuscular; Intrathecal; Iontophoresis, Solution, Solution - Intra-arterial; Intramuscular; Intravenous, Solution - Subcutaneous, Solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Liquid - Intravenous, Liquid - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Powder, for solution, Intra-arterial; Intramuscular; Intrathecal; Intravenous; Intraventricular

Medically induced abortion

25.0 mg/mL, , 2.5 mg, 100.0 mg/mL, 25.0 mg, 7.5 mg, 10.0 mg, 15.0 mg, 20.0 mg, 50.0 mg, 150.0 mg/mL, 200.0 mg/mL, 250.0 mg/mL, 75.0 mg/mL, 125.0 mg/mL, 225.0 mg/mL, 175.0 mg/mL, 12.5 mg, 17.5 mg, 22.5 mg, 5.0 mg, 1000.0 mg, 2.5 mg/mL, 275.0 mg/mL, 300.0 mg/mL, 10.0 mg/mL, 20.0 mg/mL, 15.0 mg/mL, 2.0 mg/mL

, Injection, Injection - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Injection, solution, Injection, solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Intra-arterial; Intramuscular; Intrathecal; Intravenous, Oral, Tablet - Oral, Tablet, Intra-arterial; Intramuscular; Intravenous, Injection, solution - Intra-arterial; Intramuscular; Intravenous, Intravenous, Intramuscular; Intrathecal; Intravenous, Powder, for solution - Intramuscular; Intrathecal; Intravenous, Liquid, Liquid - Intramuscular; Intrathecal; Intravenous, Solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous; Intraventricular, Powder, for solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Injection, solution - Subcutaneous, Subcutaneous, Tablet, film coated, Tablet, film coated - Oral, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Solution - Oral, Solution - Intravenous, Intra-arterial; Intramuscular; Intrathecal; Iontophoresis, Injection, solution - Intra-arterial; Intramuscular; Intrathecal; Iontophoresis, Solution, Solution - Intra-arterial; Intramuscular; Intravenous, Solution - Subcutaneous, Solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Liquid - Intravenous, Liquid - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Powder, for solution, Intra-arterial; Intramuscular; Intrathecal; Intravenous; Intraventricular

Acute Promyelocytic Leukemia

25.0 mg/mL, , 2.5 mg, 100.0 mg/mL, 25.0 mg, 7.5 mg, 10.0 mg, 15.0 mg, 20.0 mg, 50.0 mg, 150.0 mg/mL, 200.0 mg/mL, 250.0 mg/mL, 75.0 mg/mL, 125.0 mg/mL, 225.0 mg/mL, 175.0 mg/mL, 12.5 mg, 17.5 mg, 22.5 mg, 5.0 mg, 1000.0 mg, 2.5 mg/mL, 275.0 mg/mL, 300.0 mg/mL, 10.0 mg/mL, 20.0 mg/mL, 15.0 mg/mL, 2.0 mg/mL

, Injection, Injection - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Injection, solution, Injection, solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Intra-arterial; Intramuscular; Intrathecal; Intravenous, Oral, Tablet - Oral, Tablet, Intra-arterial; Intramuscular; Intravenous, Injection, solution - Intra-arterial; Intramuscular; Intravenous, Intravenous, Intramuscular; Intrathecal; Intravenous, Powder, for solution - Intramuscular; Intrathecal; Intravenous, Liquid, Liquid - Intramuscular; Intrathecal; Intravenous, Solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous; Intraventricular, Powder, for solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Injection, solution - Subcutaneous, Subcutaneous, Tablet, film coated, Tablet, film coated - Oral, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Solution - Oral, Solution - Intravenous, Intra-arterial; Intramuscular; Intrathecal; Iontophoresis, Injection, solution - Intra-arterial; Intramuscular; Intrathecal; Iontophoresis, Solution, Solution - Intra-arterial; Intramuscular; Intravenous, Solution - Subcutaneous, Solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Liquid - Intravenous, Liquid - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Powder, for solution, Intra-arterial; Intramuscular; Intrathecal; Intravenous; Intraventricular

Soft Tissue Sarcoma

25.0 mg/mL, , 2.5 mg, 100.0 mg/mL, 25.0 mg, 7.5 mg, 10.0 mg, 15.0 mg, 20.0 mg, 50.0 mg, 150.0 mg/mL, 200.0 mg/mL, 250.0 mg/mL, 75.0 mg/mL, 125.0 mg/mL, 225.0 mg/mL, 175.0 mg/mL, 12.5 mg, 17.5 mg, 22.5 mg, 5.0 mg, 1000.0 mg, 2.5 mg/mL, 275.0 mg/mL, 300.0 mg/mL, 10.0 mg/mL, 20.0 mg/mL, 15.0 mg/mL, 2.0 mg/mL

, Injection, Injection - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Injection, solution, Injection, solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Intra-arterial; Intramuscular; Intrathecal; Intravenous, Oral, Tablet - Oral, Tablet, Intra-arterial; Intramuscular; Intravenous, Injection, solution - Intra-arterial; Intramuscular; Intravenous, Intravenous, Intramuscular; Intrathecal; Intravenous, Powder, for solution - Intramuscular; Intrathecal; Intravenous, Liquid, Liquid - Intramuscular; Intrathecal; Intravenous, Solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous; Intraventricular, Powder, for solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Injection, solution - Subcutaneous, Subcutaneous, Tablet, film coated, Tablet, film coated - Oral, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Solution - Oral, Solution - Intravenous, Intra-arterial; Intramuscular; Intrathecal; Iontophoresis, Injection, solution - Intra-arterial; Intramuscular; Intrathecal; Iontophoresis, Solution, Solution - Intra-arterial; Intramuscular; Intravenous, Solution - Subcutaneous, Solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Liquid - Intravenous, Liquid - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Powder, for solution, Intra-arterial; Intramuscular; Intrathecal; Intravenous; Intraventricular

Chronic Graft Versus Host Disease

25.0 mg/mL, , 2.5 mg, 100.0 mg/mL, 25.0 mg, 7.5 mg, 10.0 mg, 15.0 mg, 20.0 mg, 50.0 mg, 150.0 mg/mL, 200.0 mg/mL, 250.0 mg/mL, 75.0 mg/mL, 125.0 mg/mL, 225.0 mg/mL, 175.0 mg/mL, 12.5 mg, 17.5 mg, 22.5 mg, 5.0 mg, 1000.0 mg, 2.5 mg/mL, 275.0 mg/mL, 300.0 mg/mL, 10.0 mg/mL, 20.0 mg/mL, 15.0 mg/mL, 2.0 mg/mL

, Injection, Injection - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Injection, solution, Injection, solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Intra-arterial; Intramuscular; Intrathecal; Intravenous, Oral, Tablet - Oral, Tablet, Intra-arterial; Intramuscular; Intravenous, Injection, solution - Intra-arterial; Intramuscular; Intravenous, Intravenous, Intramuscular; Intrathecal; Intravenous, Powder, for solution - Intramuscular; Intrathecal; Intravenous, Liquid, Liquid - Intramuscular; Intrathecal; Intravenous, Solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous; Intraventricular, Powder, for solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Injection, solution - Subcutaneous, Subcutaneous, Tablet, film coated, Tablet, film coated - Oral, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Solution - Oral, Solution - Intravenous, Intra-arterial; Intramuscular; Intrathecal; Iontophoresis, Injection, solution - Intra-arterial; Intramuscular; Intrathecal; Iontophoresis, Solution, Solution - Intra-arterial; Intramuscular; Intravenous, Solution - Subcutaneous, Solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Liquid - Intravenous, Liquid - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Powder, for solution, Intra-arterial; Intramuscular; Intrathecal; Intravenous; Intraventricular

Leukemia

25.0 mg/mL, , 2.5 mg, 100.0 mg/mL, 25.0 mg, 7.5 mg, 10.0 mg, 15.0 mg, 20.0 mg, 50.0 mg, 150.0 mg/mL, 200.0 mg/mL, 250.0 mg/mL, 75.0 mg/mL, 125.0 mg/mL, 225.0 mg/mL, 175.0 mg/mL, 12.5 mg, 17.5 mg, 22.5 mg, 5.0 mg, 1000.0 mg, 2.5 mg/mL, 275.0 mg/mL, 300.0 mg/mL, 10.0 mg/mL, 20.0 mg/mL, 15.0 mg/mL, 2.0 mg/mL

, Injection, Injection - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Injection, solution, Injection, solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Intra-arterial; Intramuscular; Intrathecal; Intravenous, Oral, Tablet - Oral, Tablet, Intra-arterial; Intramuscular; Intravenous, Injection, solution - Intra-arterial; Intramuscular; Intravenous, Intravenous, Intramuscular; Intrathecal; Intravenous, Powder, for solution - Intramuscular; Intrathecal; Intravenous, Liquid, Liquid - Intramuscular; Intrathecal; Intravenous, Solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous; Intraventricular, Powder, for solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Injection, solution - Subcutaneous, Subcutaneous, Tablet, film coated, Tablet, film coated - Oral, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Solution - Oral, Solution - Intravenous, Intra-arterial; Intramuscular; Intrathecal; Iontophoresis, Injection, solution - Intra-arterial; Intramuscular; Intrathecal; Iontophoresis, Solution, Solution - Intra-arterial; Intramuscular; Intravenous, Solution - Subcutaneous, Solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Liquid - Intravenous, Liquid - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Powder, for solution, Intra-arterial; Intramuscular; Intrathecal; Intravenous; Intraventricular

Arthritis, Juvenile

25.0 mg/mL, , 2.5 mg, 100.0 mg/mL, 25.0 mg, 7.5 mg, 10.0 mg, 15.0 mg, 20.0 mg, 50.0 mg, 150.0 mg/mL, 200.0 mg/mL, 250.0 mg/mL, 75.0 mg/mL, 125.0 mg/mL, 225.0 mg/mL, 175.0 mg/mL, 12.5 mg, 17.5 mg, 22.5 mg, 5.0 mg, 1000.0 mg, 2.5 mg/mL, 275.0 mg/mL, 300.0 mg/mL, 10.0 mg/mL, 20.0 mg/mL, 15.0 mg/mL, 2.0 mg/mL

, Injection, Injection - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Injection, solution, Injection, solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Intra-arterial; Intramuscular; Intrathecal; Intravenous, Oral, Tablet - Oral, Tablet, Intra-arterial; Intramuscular; Intravenous, Injection, solution - Intra-arterial; Intramuscular; Intravenous, Intravenous, Intramuscular; Intrathecal; Intravenous, Powder, for solution - Intramuscular; Intrathecal; Intravenous, Liquid, Liquid - Intramuscular; Intrathecal; Intravenous, Solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous; Intraventricular, Powder, for solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Injection, solution - Subcutaneous, Subcutaneous, Tablet, film coated, Tablet, film coated - Oral, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Solution - Oral, Solution - Intravenous, Intra-arterial; Intramuscular; Intrathecal; Iontophoresis, Injection, solution - Intra-arterial; Intramuscular; Intrathecal; Iontophoresis, Solution, Solution - Intra-arterial; Intramuscular; Intravenous, Solution - Subcutaneous, Solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Liquid - Intravenous, Liquid - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Powder, for solution, Intra-arterial; Intramuscular; Intrathecal; Intravenous; Intraventricular

Polymyositis

25.0 mg/mL, , 2.5 mg, 100.0 mg/mL, 25.0 mg, 7.5 mg, 10.0 mg, 15.0 mg, 20.0 mg, 50.0 mg, 150.0 mg/mL, 200.0 mg/mL, 250.0 mg/mL, 75.0 mg/mL, 125.0 mg/mL, 225.0 mg/mL, 175.0 mg/mL, 12.5 mg, 17.5 mg, 22.5 mg, 5.0 mg, 1000.0 mg, 2.5 mg/mL, 275.0 mg/mL, 300.0 mg/mL, 10.0 mg/mL, 20.0 mg/mL, 15.0 mg/mL, 2.0 mg/mL

, Injection, Injection - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Injection, solution, Injection, solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Intra-arterial; Intramuscular; Intrathecal; Intravenous, Oral, Tablet - Oral, Tablet, Intra-arterial; Intramuscular; Intravenous, Injection, solution - Intra-arterial; Intramuscular; Intravenous, Intravenous, Intramuscular; Intrathecal; Intravenous, Powder, for solution - Intramuscular; Intrathecal; Intravenous, Liquid, Liquid - Intramuscular; Intrathecal; Intravenous, Solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous; Intraventricular, Powder, for solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Injection, solution - Subcutaneous, Subcutaneous, Tablet, film coated, Tablet, film coated - Oral, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Solution - Oral, Solution - Intravenous, Intra-arterial; Intramuscular; Intrathecal; Iontophoresis, Injection, solution - Intra-arterial; Intramuscular; Intrathecal; Iontophoresis, Solution, Solution - Intra-arterial; Intramuscular; Intravenous, Solution - Subcutaneous, Solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Liquid - Intravenous, Liquid - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Powder, for solution, Intra-arterial; Intramuscular; Intrathecal; Intravenous; Intraventricular

Uveitis

25.0 mg/mL, , 2.5 mg, 100.0 mg/mL, 25.0 mg, 7.5 mg, 10.0 mg, 15.0 mg, 20.0 mg, 50.0 mg, 150.0 mg/mL, 200.0 mg/mL, 250.0 mg/mL, 75.0 mg/mL, 125.0 mg/mL, 225.0 mg/mL, 175.0 mg/mL, 12.5 mg, 17.5 mg, 22.5 mg, 5.0 mg, 1000.0 mg, 2.5 mg/mL, 275.0 mg/mL, 300.0 mg/mL, 10.0 mg/mL, 20.0 mg/mL, 15.0 mg/mL, 2.0 mg/mL

, Injection, Injection - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Injection, solution, Injection, solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Intra-arterial; Intramuscular; Intrathecal; Intravenous, Oral, Tablet - Oral, Tablet, Intra-arterial; Intramuscular; Intravenous, Injection, solution - Intra-arterial; Intramuscular; Intravenous, Intravenous, Intramuscular; Intrathecal; Intravenous, Powder, for solution - Intramuscular; Intrathecal; Intravenous, Liquid, Liquid - Intramuscular; Intrathecal; Intravenous, Solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous; Intraventricular, Powder, for solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Injection, solution - Subcutaneous, Subcutaneous, Tablet, film coated, Tablet, film coated - Oral, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Solution - Oral, Solution - Intravenous, Intra-arterial; Intramuscular; Intrathecal; Iontophoresis, Injection, solution - Intra-arterial; Intramuscular; Intrathecal; Iontophoresis, Solution, Solution - Intra-arterial; Intramuscular; Intravenous, Solution - Subcutaneous, Solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Liquid - Intravenous, Liquid - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Powder, for solution, Intra-arterial; Intramuscular; Intrathecal; Intravenous; Intraventricular

Chemotherapy

25.0 mg/mL, , 2.5 mg, 100.0 mg/mL, 25.0 mg, 7.5 mg, 10.0 mg, 15.0 mg, 20.0 mg, 50.0 mg, 150.0 mg/mL, 200.0 mg/mL, 250.0 mg/mL, 75.0 mg/mL, 125.0 mg/mL, 225.0 mg/mL, 175.0 mg/mL, 12.5 mg, 17.5 mg, 22.5 mg, 5.0 mg, 1000.0 mg, 2.5 mg/mL, 275.0 mg/mL, 300.0 mg/mL, 10.0 mg/mL, 20.0 mg/mL, 15.0 mg/mL, 2.0 mg/mL

, Injection, Injection - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Injection, solution, Injection, solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Intra-arterial; Intramuscular; Intrathecal; Intravenous, Oral, Tablet - Oral, Tablet, Intra-arterial; Intramuscular; Intravenous, Injection, solution - Intra-arterial; Intramuscular; Intravenous, Intravenous, Intramuscular; Intrathecal; Intravenous, Powder, for solution - Intramuscular; Intrathecal; Intravenous, Liquid, Liquid - Intramuscular; Intrathecal; Intravenous, Solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous; Intraventricular, Powder, for solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Injection, solution - Subcutaneous, Subcutaneous, Tablet, film coated, Tablet, film coated - Oral, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Solution - Oral, Solution - Intravenous, Intra-arterial; Intramuscular; Intrathecal; Iontophoresis, Injection, solution - Intra-arterial; Intramuscular; Intrathecal; Iontophoresis, Solution, Solution - Intra-arterial; Intramuscular; Intravenous, Solution - Subcutaneous, Solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Liquid - Intravenous, Liquid - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Powder, for solution, Intra-arterial; Intramuscular; Intrathecal; Intravenous; Intraventricular

Psoriasis

25.0 mg/mL, , 2.5 mg, 100.0 mg/mL, 25.0 mg, 7.5 mg, 10.0 mg, 15.0 mg, 20.0 mg, 50.0 mg, 150.0 mg/mL, 200.0 mg/mL, 250.0 mg/mL, 75.0 mg/mL, 125.0 mg/mL, 225.0 mg/mL, 175.0 mg/mL, 12.5 mg, 17.5 mg, 22.5 mg, 5.0 mg, 1000.0 mg, 2.5 mg/mL, 275.0 mg/mL, 300.0 mg/mL, 10.0 mg/mL, 20.0 mg/mL, 15.0 mg/mL, 2.0 mg/mL

, Injection, Injection - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Injection, solution, Injection, solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Intra-arterial; Intramuscular; Intrathecal; Intravenous, Oral, Tablet - Oral, Tablet, Intra-arterial; Intramuscular; Intravenous, Injection, solution - Intra-arterial; Intramuscular; Intravenous, Intravenous, Intramuscular; Intrathecal; Intravenous, Powder, for solution - Intramuscular; Intrathecal; Intravenous, Liquid, Liquid - Intramuscular; Intrathecal; Intravenous, Solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous; Intraventricular, Powder, for solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Injection, solution - Subcutaneous, Subcutaneous, Tablet, film coated, Tablet, film coated - Oral, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Solution - Oral, Solution - Intravenous, Intra-arterial; Intramuscular; Intrathecal; Iontophoresis, Injection, solution - Intra-arterial; Intramuscular; Intrathecal; Iontophoresis, Solution, Solution - Intra-arterial; Intramuscular; Intravenous, Solution - Subcutaneous, Solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Liquid - Intravenous, Liquid - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Powder, for solution, Intra-arterial; Intramuscular; Intrathecal; Intravenous; Intraventricular

Leukemia

25.0 mg/mL, , 2.5 mg, 100.0 mg/mL, 25.0 mg, 7.5 mg, 10.0 mg, 15.0 mg, 20.0 mg, 50.0 mg, 150.0 mg/mL, 200.0 mg/mL, 250.0 mg/mL, 75.0 mg/mL, 125.0 mg/mL, 225.0 mg/mL, 175.0 mg/mL, 12.5 mg, 17.5 mg, 22.5 mg, 5.0 mg, 1000.0 mg, 2.5 mg/mL, 275.0 mg/mL, 300.0 mg/mL, 10.0 mg/mL, 20.0 mg/mL, 15.0 mg/mL, 2.0 mg/mL

, Injection, Injection - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Injection, solution, Injection, solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Intra-arterial; Intramuscular; Intrathecal; Intravenous, Oral, Tablet - Oral, Tablet, Intra-arterial; Intramuscular; Intravenous, Injection, solution - Intra-arterial; Intramuscular; Intravenous, Intravenous, Intramuscular; Intrathecal; Intravenous, Powder, for solution - Intramuscular; Intrathecal; Intravenous, Liquid, Liquid - Intramuscular; Intrathecal; Intravenous, Solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous; Intraventricular, Powder, for solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Injection, solution - Subcutaneous, Subcutaneous, Tablet, film coated, Tablet, film coated - Oral, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Solution - Oral, Solution - Intravenous, Intra-arterial; Intramuscular; Intrathecal; Iontophoresis, Injection, solution - Intra-arterial; Intramuscular; Intrathecal; Iontophoresis, Solution, Solution - Intra-arterial; Intramuscular; Intravenous, Solution - Subcutaneous, Solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Liquid - Intravenous, Liquid - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Powder, for solution, Intra-arterial; Intramuscular; Intrathecal; Intravenous; Intraventricular

Lymphoma, Non-Hodgkin

25.0 mg/mL, , 2.5 mg, 100.0 mg/mL, 25.0 mg, 7.5 mg, 10.0 mg, 15.0 mg, 20.0 mg, 50.0 mg, 150.0 mg/mL, 200.0 mg/mL, 250.0 mg/mL, 75.0 mg/mL, 125.0 mg/mL, 225.0 mg/mL, 175.0 mg/mL, 12.5 mg, 17.5 mg, 22.5 mg, 5.0 mg, 1000.0 mg, 2.5 mg/mL, 275.0 mg/mL, 300.0 mg/mL, 10.0 mg/mL, 20.0 mg/mL, 15.0 mg/mL, 2.0 mg/mL

, Injection, Injection - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Injection, solution, Injection, solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Intra-arterial; Intramuscular; Intrathecal; Intravenous, Oral, Tablet - Oral, Tablet, Intra-arterial; Intramuscular; Intravenous, Injection, solution - Intra-arterial; Intramuscular; Intravenous, Intravenous, Intramuscular; Intrathecal; Intravenous, Powder, for solution - Intramuscular; Intrathecal; Intravenous, Liquid, Liquid - Intramuscular; Intrathecal; Intravenous, Solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous; Intraventricular, Powder, for solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Injection, solution - Subcutaneous, Subcutaneous, Tablet, film coated, Tablet, film coated - Oral, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Solution - Oral, Solution - Intravenous, Intra-arterial; Intramuscular; Intrathecal; Iontophoresis, Injection, solution - Intra-arterial; Intramuscular; Intrathecal; Iontophoresis, Solution, Solution - Intra-arterial; Intramuscular; Intravenous, Solution - Subcutaneous, Solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Liquid - Intravenous, Liquid - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Powder, for solution, Intra-arterial; Intramuscular; Intrathecal; Intravenous; Intraventricular

Dermatomyositis

25.0 mg/mL, , 2.5 mg, 100.0 mg/mL, 25.0 mg, 7.5 mg, 10.0 mg, 15.0 mg, 20.0 mg, 50.0 mg, 150.0 mg/mL, 200.0 mg/mL, 250.0 mg/mL, 75.0 mg/mL, 125.0 mg/mL, 225.0 mg/mL, 175.0 mg/mL, 12.5 mg, 17.5 mg, 22.5 mg, 5.0 mg, 1000.0 mg, 2.5 mg/mL, 275.0 mg/mL, 300.0 mg/mL, 10.0 mg/mL, 20.0 mg/mL, 15.0 mg/mL, 2.0 mg/mL

, Injection, Injection - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Injection, solution, Injection, solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Intra-arterial; Intramuscular; Intrathecal; Intravenous, Oral, Tablet - Oral, Tablet, Intra-arterial; Intramuscular; Intravenous, Injection, solution - Intra-arterial; Intramuscular; Intravenous, Intravenous, Intramuscular; Intrathecal; Intravenous, Powder, for solution - Intramuscular; Intrathecal; Intravenous, Liquid, Liquid - Intramuscular; Intrathecal; Intravenous, Solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous; Intraventricular, Powder, for solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Injection, solution - Subcutaneous, Subcutaneous, Tablet, film coated, Tablet, film coated - Oral, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Solution - Oral, Solution - Intravenous, Intra-arterial; Intramuscular; Intrathecal; Iontophoresis, Injection, solution - Intra-arterial; Intramuscular; Intrathecal; Iontophoresis, Solution, Solution - Intra-arterial; Intramuscular; Intravenous, Solution - Subcutaneous, Solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Liquid - Intravenous, Liquid - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Powder, for solution, Intra-arterial; Intramuscular; Intrathecal; Intravenous; Intraventricular

Multiple Sclerosis

25.0 mg/mL, , 2.5 mg, 100.0 mg/mL, 25.0 mg, 7.5 mg, 10.0 mg, 15.0 mg, 20.0 mg, 50.0 mg, 150.0 mg/mL, 200.0 mg/mL, 250.0 mg/mL, 75.0 mg/mL, 125.0 mg/mL, 225.0 mg/mL, 175.0 mg/mL, 12.5 mg, 17.5 mg, 22.5 mg, 5.0 mg, 1000.0 mg, 2.5 mg/mL, 275.0 mg/mL, 300.0 mg/mL, 10.0 mg/mL, 20.0 mg/mL, 15.0 mg/mL, 2.0 mg/mL

, Injection, Injection - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Injection, solution, Injection, solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Intra-arterial; Intramuscular; Intrathecal; Intravenous, Oral, Tablet - Oral, Tablet, Intra-arterial; Intramuscular; Intravenous, Injection, solution - Intra-arterial; Intramuscular; Intravenous, Intravenous, Intramuscular; Intrathecal; Intravenous, Powder, for solution - Intramuscular; Intrathecal; Intravenous, Liquid, Liquid - Intramuscular; Intrathecal; Intravenous, Solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous; Intraventricular, Powder, for solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Injection, solution - Subcutaneous, Subcutaneous, Tablet, film coated, Tablet, film coated - Oral, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Solution - Oral, Solution - Intravenous, Intra-arterial; Intramuscular; Intrathecal; Iontophoresis, Injection, solution - Intra-arterial; Intramuscular; Intrathecal; Iontophoresis, Solution, Solution - Intra-arterial; Intramuscular; Intravenous, Solution - Subcutaneous, Solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Liquid - Intravenous, Liquid - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Powder, for solution, Intra-arterial; Intramuscular; Intrathecal; Intravenous; Intraventricular

Breast Cancer

25.0 mg/mL, , 2.5 mg, 100.0 mg/mL, 25.0 mg, 7.5 mg, 10.0 mg, 15.0 mg, 20.0 mg, 50.0 mg, 150.0 mg/mL, 200.0 mg/mL, 250.0 mg/mL, 75.0 mg/mL, 125.0 mg/mL, 225.0 mg/mL, 175.0 mg/mL, 12.5 mg, 17.5 mg, 22.5 mg, 5.0 mg, 1000.0 mg, 2.5 mg/mL, 275.0 mg/mL, 300.0 mg/mL, 10.0 mg/mL, 20.0 mg/mL, 15.0 mg/mL, 2.0 mg/mL

, Injection, Injection - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Injection, solution, Injection, solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Intra-arterial; Intramuscular; Intrathecal; Intravenous, Oral, Tablet - Oral, Tablet, Intra-arterial; Intramuscular; Intravenous, Injection, solution - Intra-arterial; Intramuscular; Intravenous, Intravenous, Intramuscular; Intrathecal; Intravenous, Powder, for solution - Intramuscular; Intrathecal; Intravenous, Liquid, Liquid - Intramuscular; Intrathecal; Intravenous, Solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous; Intraventricular, Powder, for solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Injection, solution - Subcutaneous, Subcutaneous, Tablet, film coated, Tablet, film coated - Oral, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Solution - Oral, Solution - Intravenous, Intra-arterial; Intramuscular; Intrathecal; Iontophoresis, Injection, solution - Intra-arterial; Intramuscular; Intrathecal; Iontophoresis, Solution, Solution - Intra-arterial; Intramuscular; Intravenous, Solution - Subcutaneous, Solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Liquid - Intravenous, Liquid - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Powder, for solution, Intra-arterial; Intramuscular; Intrathecal; Intravenous; Intraventricular

Lymphoma

25.0 mg/mL, , 2.5 mg, 100.0 mg/mL, 25.0 mg, 7.5 mg, 10.0 mg, 15.0 mg, 20.0 mg, 50.0 mg, 150.0 mg/mL, 200.0 mg/mL, 250.0 mg/mL, 75.0 mg/mL, 125.0 mg/mL, 225.0 mg/mL, 175.0 mg/mL, 12.5 mg, 17.5 mg, 22.5 mg, 5.0 mg, 1000.0 mg, 2.5 mg/mL, 275.0 mg/mL, 300.0 mg/mL, 10.0 mg/mL, 20.0 mg/mL, 15.0 mg/mL, 2.0 mg/mL

, Injection, Injection - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Injection, solution, Injection, solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Intra-arterial; Intramuscular; Intrathecal; Intravenous, Oral, Tablet - Oral, Tablet, Intra-arterial; Intramuscular; Intravenous, Injection, solution - Intra-arterial; Intramuscular; Intravenous, Intravenous, Intramuscular; Intrathecal; Intravenous, Powder, for solution - Intramuscular; Intrathecal; Intravenous, Liquid, Liquid - Intramuscular; Intrathecal; Intravenous, Solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous; Intraventricular, Powder, for solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Injection, solution - Subcutaneous, Subcutaneous, Tablet, film coated, Tablet, film coated - Oral, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Solution - Oral, Solution - Intravenous, Intra-arterial; Intramuscular; Intrathecal; Iontophoresis, Injection, solution - Intra-arterial; Intramuscular; Intrathecal; Iontophoresis, Solution, Solution - Intra-arterial; Intramuscular; Intravenous, Solution - Subcutaneous, Solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Liquid - Intravenous, Liquid - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Powder, for solution, Intra-arterial; Intramuscular; Intrathecal; Intravenous; Intraventricular

Crohn's Disease

25.0 mg/mL, , 2.5 mg, 100.0 mg/mL, 25.0 mg, 7.5 mg, 10.0 mg, 15.0 mg, 20.0 mg, 50.0 mg, 150.0 mg/mL, 200.0 mg/mL, 250.0 mg/mL, 75.0 mg/mL, 125.0 mg/mL, 225.0 mg/mL, 175.0 mg/mL, 12.5 mg, 17.5 mg, 22.5 mg, 5.0 mg, 1000.0 mg, 2.5 mg/mL, 275.0 mg/mL, 300.0 mg/mL, 10.0 mg/mL, 20.0 mg/mL, 15.0 mg/mL, 2.0 mg/mL

, Injection, Injection - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Injection, solution, Injection, solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Intra-arterial; Intramuscular; Intrathecal; Intravenous, Oral, Tablet - Oral, Tablet, Intra-arterial; Intramuscular; Intravenous, Injection, solution - Intra-arterial; Intramuscular; Intravenous, Intravenous, Intramuscular; Intrathecal; Intravenous, Powder, for solution - Intramuscular; Intrathecal; Intravenous, Liquid, Liquid - Intramuscular; Intrathecal; Intravenous, Solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous; Intraventricular, Powder, for solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Injection, solution - Subcutaneous, Subcutaneous, Tablet, film coated, Tablet, film coated - Oral, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Solution - Oral, Solution - Intravenous, Intra-arterial; Intramuscular; Intrathecal; Iontophoresis, Injection, solution - Intra-arterial; Intramuscular; Intrathecal; Iontophoresis, Solution, Solution - Intra-arterial; Intramuscular; Intravenous, Solution - Subcutaneous, Solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Liquid - Intravenous, Liquid - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Powder, for solution, Intra-arterial; Intramuscular; Intrathecal; Intravenous; Intraventricular

Lupus

25.0 mg/mL, , 2.5 mg, 100.0 mg/mL, 25.0 mg, 7.5 mg, 10.0 mg, 15.0 mg, 20.0 mg, 50.0 mg, 150.0 mg/mL, 200.0 mg/mL, 250.0 mg/mL, 75.0 mg/mL, 125.0 mg/mL, 225.0 mg/mL, 175.0 mg/mL, 12.5 mg, 17.5 mg, 22.5 mg, 5.0 mg, 1000.0 mg, 2.5 mg/mL, 275.0 mg/mL, 300.0 mg/mL, 10.0 mg/mL, 20.0 mg/mL, 15.0 mg/mL, 2.0 mg/mL

, Injection, Injection - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Injection, solution, Injection, solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Intra-arterial; Intramuscular; Intrathecal; Intravenous, Oral, Tablet - Oral, Tablet, Intra-arterial; Intramuscular; Intravenous, Injection, solution - Intra-arterial; Intramuscular; Intravenous, Intravenous, Intramuscular; Intrathecal; Intravenous, Powder, for solution - Intramuscular; Intrathecal; Intravenous, Liquid, Liquid - Intramuscular; Intrathecal; Intravenous, Solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous; Intraventricular, Powder, for solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Injection, solution - Subcutaneous, Subcutaneous, Tablet, film coated, Tablet, film coated - Oral, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Solution - Oral, Solution - Intravenous, Intra-arterial; Intramuscular; Intrathecal; Iontophoresis, Injection, solution - Intra-arterial; Intramuscular; Intrathecal; Iontophoresis, Solution, Solution - Intra-arterial; Intramuscular; Intravenous, Solution - Subcutaneous, Solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Liquid - Intravenous, Liquid - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Powder, for solution, Intra-arterial; Intramuscular; Intrathecal; Intravenous; Intraventricular

Pregnancy, Ectopic

25.0 mg/mL, , 2.5 mg, 100.0 mg/mL, 25.0 mg, 7.5 mg, 10.0 mg, 15.0 mg, 20.0 mg, 50.0 mg, 150.0 mg/mL, 200.0 mg/mL, 250.0 mg/mL, 75.0 mg/mL, 125.0 mg/mL, 225.0 mg/mL, 175.0 mg/mL, 12.5 mg, 17.5 mg, 22.5 mg, 5.0 mg, 1000.0 mg, 2.5 mg/mL, 275.0 mg/mL, 300.0 mg/mL, 10.0 mg/mL, 20.0 mg/mL, 15.0 mg/mL, 2.0 mg/mL

, Injection, Injection - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Injection, solution, Injection, solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Intra-arterial; Intramuscular; Intrathecal; Intravenous, Oral, Tablet - Oral, Tablet, Intra-arterial; Intramuscular; Intravenous, Injection, solution - Intra-arterial; Intramuscular; Intravenous, Intravenous, Intramuscular; Intrathecal; Intravenous, Powder, for solution - Intramuscular; Intrathecal; Intravenous, Liquid, Liquid - Intramuscular; Intrathecal; Intravenous, Solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous; Intraventricular, Powder, for solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Injection, solution - Subcutaneous, Subcutaneous, Tablet, film coated, Tablet, film coated - Oral, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Solution - Oral, Solution - Intravenous, Intra-arterial; Intramuscular; Intrathecal; Iontophoresis, Injection, solution - Intra-arterial; Intramuscular; Intrathecal; Iontophoresis, Solution, Solution - Intra-arterial; Intramuscular; Intravenous, Solution - Subcutaneous, Solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Liquid - Intravenous, Liquid - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Powder, for solution, Intra-arterial; Intramuscular; Intrathecal; Intravenous; Intraventricular

Warnings

Trexall Contraindications

Condition

Risk Level

Notes

Non Neoplastic Condition

Do Not Combine

Severe Hypersensitivity Reactions

Do Not Combine

Methotrexate may interact with Pulse Frequency

There are 20 known major drug interactions with Trexall.

Common Trexall Drug Interactions

Drug Name

Risk Level

Description

2-Methoxyethanol

Major

The risk or severity of adverse effects can be increased when Methotrexate is combined with 2-Methoxyethanol.

9-(N-methyl-L-isoleucine)-cyclosporin A

Major

The risk or severity of adverse effects can be increased when Methotrexate is combined with 9-(N-methyl-L-isoleucine)-cyclosporin A.

Abetimus

Major

The risk or severity of adverse effects can be increased when Methotrexate is combined with Abetimus.

Acteoside

Major

The risk or severity of adverse effects can be increased when Methotrexate is combined with Acteoside.

Aldosterone

Major

The risk or severity of adverse effects can be increased when Methotrexate is combined with Aldosterone.

Trexall Toxicity & Overdose Risk

The lowest toxic dose of this drug in rats is 135mg/kg and in mice is 146mg/kg. Overdosing on this drug may cause low blood cell counts, mouth sores, nausea, vomiting, stomach ulcers, and bleeding from the digestive tract. If a patient overdoses, they should be treated with glucarpidase and should not be given leucovorin for 2 hours before or after glucarpidase.

image of a doctor in a lab doing drug, clinical research

Trexall Novel Uses: Which Conditions Have a Clinical Trial Featuring Trexall?

There are 764 active investigations into the potential of Trexall to treat Uveitis, Small Cell Lung Cancer and Soft Tissue Sarcoma.

Condition

Clinical Trials

Trial Phases

Soft Tissue Sarcoma

51 Actively Recruiting

Phase 2, Not Applicable, Phase 1, Phase 4, Early Phase 1, Phase 3

Non-Hodgkin's Lymphoma

115 Actively Recruiting

Phase 1, Phase 2, Not Applicable, Phase 3, Early Phase 1, Phase 4

Lupus

65 Actively Recruiting

Phase 2, Not Applicable, Phase 1, Phase 3, Phase 4, Early Phase 1

Bladder Cancer

101 Actively Recruiting

Phase 2, Not Applicable, Phase 1, Phase 3, Early Phase 1

Acute Lymphoblastic Leukemia

120 Actively Recruiting

Phase 1, Phase 2, Phase 3, Not Applicable, Early Phase 1, Phase 4

Multiple Sclerosis

127 Actively Recruiting

Phase 3, Not Applicable, Phase 4, Phase 2, Phase 1, Early Phase 1

Rheumatoid Arthritis

55 Actively Recruiting

Not Applicable, Phase 4, Phase 3, Phase 2, Phase 1

Hematopoietic stem cells

3 Actively Recruiting

Early Phase 1, Phase 1, Phase 2

Takayasu Arteritis

1 Actively Recruiting

Phase 2

Psoriasis

0 Actively Recruiting

Mycosis Fungoides

0 Actively Recruiting

Chemotherapy

4 Actively Recruiting

Phase 1, Phase 3, Not Applicable

Crohn's Disease

54 Actively Recruiting

Phase 1, Phase 2, Not Applicable, Phase 3, Phase 4, Early Phase 1

Acute Promyelocytic Leukemia

0 Actively Recruiting

Breast Cancer

21 Actively Recruiting

Phase 2, Phase 1, Not Applicable

Sarcoma

0 Actively Recruiting

Lymphoma

4 Actively Recruiting

Phase 1, Phase 2

Gestational Trophoblastic Disease

0 Actively Recruiting

Pregnancy, Ectopic

0 Actively Recruiting

Polymyositis

3 Actively Recruiting

Phase 2, Phase 3

Trexall Reviews: What are patients saying about Trexall?

5

Patient Review

5/19/2010

Trexall for Rheumatoid Arthritis

I've used this treatment for two years now and it has worked well for me. I'm currently taking 8 2.5 mg doses per week, but I recently tried cutting down to 6 because I was feeling so well and didn't like the possible side effects. However, I found that my pain increased and my mobility decreased, so with my doctor's approval, I will probably go back up to 8 doses per week.

4.3

Patient Review

7/20/2009

Trexall for Rheumatoid Arthritis

I've had RA for a decade and been on methotrexate off-and-on for a couple years now. I'm currently 1.5 years into another cycle and it's helping moderately well; better than most other options available to me, at any rate. That said, it does make me tired and nauseous every dosage, which isn't ideal.

4.3

Patient Review

7/19/2013

Trexall for Inflammation of Skin and Muscles All Over the Body

I've had some indigestion, reflux and chest pains since starting this medication, but it's only been three doses.

3.7

Patient Review

10/24/2008

Trexall for Rheumatoid Arthritis

I've been taking methotrexate for nearly a year now, and I don't see any change in my current psoriasis areas. If anything, it seems like I'm getting new breakouts.

3

Patient Review

10/23/2012

Trexall for Rheumatoid Arthritis

Please be aware that long-term use of this drug may lead to diabetes. My husband developed blue toe syndrome and had to have a toe removed as a result.

2

Patient Review

10/3/2008

Trexall for Psoriasis

image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about trexall

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What are the common side effects of methotrexate?

"Dizziness, drowsiness, headache, swollen, tender gums, decreased appetite, reddened eyes, and hair loss are all potential side effects of the medication."

Answered by AI

How long does it take for Trexall to work?

"Methotrexate requires regular laboratory monitoring in order to keep track of blood counts and the patient's liver function. The drug usually produces improvements in arthritis and other conditions within three to six weeks, although the full benefits of the drug may not be seen for 12 weeks."

Answered by AI

What is the difference between Trexall and methotrexate?

"Trexall is a brand-name medication that contains the active drug methotrexate. Methotrexate is the ingredient that makes Trexall work. Generic forms of methotrexate tablets are available, but these come in a lower strength (2.5 mg) than Trexall."

Answered by AI

What is the drug Trexall used for?

"Methotrexate is a medication that is used as a treatment for cancer, severe psoriasis, or rheumatoid arthritis. It is typically given to patients who have not responded well to other forms of treatment."

Answered by AI

Clinical Trials for Trexall

Image of Ohio State University Comprehensive Cancer Center in Columbus, United States.

Ruxolitinib for T-Cell Lymphoma

18+
All Sexes
Columbus, OH

This phase II trial tests how well ruxolitinib as a maintenance medication works to prevent relapse and graft-versus-host disease (GVHD) for patients who have undergone stem cell transplantation for T-cell lymphoma. GVHD is a common problem that may occur after a blood stem cell transplant. The "graft" is the donor blood cells that patients get during the transplant. The "host" is the person receiving the cells. GVHD is when the donor graft attacks and damages some of the transplant recipient's tissues. Ruxolitinib is a type of drug called a Janus kinase (JAK) inhibitor which works by decreasing the immune response of cells in the body. It is also a cancer growth blocker that blocks the growth factors that trigger the cancer cells to divide and grow. Ruxolitinib works by blocking a gene, called JAK2, that is important in the production of cancer cells.

Phase 2
Recruiting

Ohio State University Comprehensive Cancer Center

Jonathan Brammer, MD

Incyte Corporation

Image of University of Illinois at Chicago in Chicago, United States.

Functional Balance Intervention for Multiple Sclerosis

40 - 90
All Sexes
Chicago, IL

The study involves a two-arm, Phase 1, randomized controlled clinical trial designed to establish the feasibility and effects of a Functional Balance Intervention (FBI) on physical and cognitive function, as well as measures of daily living among persons with multiple sclerosis (PwMS). Combined Specific Aims: Aim 1: Examine the effect of the FBI (Intervention Group) on physical function in PwMS compared to a stretching program (Control Group). Hypothesis 1: After four months of training, the FBI group will show significantly greater improvements in physical function compared to the stretching group. Aim 2: Examine the effect of the multicomponent FBI on cognitive function in PwMS compared to the stretching program. Hypothesis 2: After four months of training, the FBI group will show significantly greater improvements in cognitive function compared to the stretching group. Aim 3: Examine the effects of the multicomponent FBI compared to the Control Group among PwMS on measures of daily living (dual-task performance, balance confidence, community mobility, and quality of life). Hypothesis 3: After four months of training, the FBI group will show significantly greater improvements in measures of daily living compared to the stretching group. All assessment sessions will be conducted virtually via Zoom. All measures collected during the initial screening, pre-training assessment, training progression, and mid- and post-training assessment sessions will be administered either via Zoom with a Helper Buddy present or through survey links sent to participants via the UIC REDCap system. The training sessions will be performed independently by the participants in the presence of a Helper Buddy. The investigators will recruit 75 people with multiple sclerosis (PwMS) for this study. Eligible participants will be randomized to either the FBI (Intervention) or stretching (Control) group, followed by an onboarding session with a designated Helper Buddy. Training will occur twice weekly for four months. Based on the anticipated attrition rate, the investigators aim for 40 PwMS to complete the post-training assessments and finish the study.

Recruiting
Has No Placebo

University of Illinois at Chicago

Image of National Institutes of Health Clinical Center in Bethesda, United States.

CD22 CAR T-cells for Acute Lymphoblastic Leukemia

3 - 65
All Sexes
Bethesda, MD

Background: Acute lymphoblastic leukemia (ALL) is a type of blood cancer. Chimeric antigen receptor (CAR) therapy involves taking immune cells (T cells) from a person and modifying them to better target cancer cells. CAR T-cell therapy that targets a marker called CD19 has been show to can cure ALL in many children and adults. But in about 50% of patients, the ALL comes back within a year. Researchers want to find out if a second treatment with CAR T-cell therapy that targets a different marker, CD22, can keep the cancer away longer. Objective: To see if CD22 CAR T-cell therapy can keep ALL away longer. Eligibility: People aged 3 to 65 years who have no signs of cancer after CD19 CAR T-cell treatment for ALL. Design: Participants will be screened. They will have imaging scans and tests of their heart function. A sample of tissue (biopsy) will be collected from their bone marrow. They will have a fluid sample collected from the area around their spinal cord. Participants will undergo collection of their white blood cells (T cells) during a procedure called leukapheresis. Blood will be taken from their body through a vein. The blood will pass through a machine that separates out the T cells. The remaining blood will be returned to the body through a different vein. The cells will be altered in a lab to create CD22 CAR T-cell therapy. Participants will take drugs over 4 consecutive days to prepare their body for the CAR T-cell therapy; then they will receive their modified T cells through a tube inserted into a vein. Some people may need to stay in the hospital during treatment. Participants will have follow-up visits for 2 years.

Phase 2
Waitlist Available

National Institutes of Health Clinical Center

Sara K Silbert, M.D.

Have you considered Trexall clinical trials?

We made a collection of clinical trials featuring Trexall, we think they might fit your search criteria.
Go to Trials
Image of The University of British Columbia in Vancouver, Canada.

Nutritional Therapy + Anti-TNFα for Crohn's Disease

9 - 17
All Sexes
Vancouver, Canada

Children with Crohn's disease (CD), a type of Inflammatory Bowel Disease (IBD), often face serious health challenges, including poor growth, frequent hospital stays, and long-term medication use. Although biologic drugs like infliximab, an anti-TNFα (Tumor necrosis factor α) medication, have improved treatment, they don't work for everyone: many children still experience symptoms or disease flare-ups. Nutritional therapies, especially the Crohn's Disease Exclusion Diet (CDED), may help improve treatment outcomes. This study will assess whether starting CDED at the same time as infliximab leads to better responses to treatment. The goal of this study is to improve how well children respond to therapy, reduce drug exposure, and support better long-term health.

Waitlist Available
Has No Placebo

The University of British Columbia

Kevan Jacobson, MBBCh, FRCP, FRCPC, AGAF, CAGF

Image of MUHC - Montreal General Hospital in Montreal, Canada.

Ustekinumab for Crohn's Disease and Ulcerative Colitis

18+
All Sexes
Montreal, Canada

The goal of this clinical trial is to evaluate whether disease remission can be maintained when biologic therapy is reduced in patients with Crohn"s disease (CD) and ulcerative colitis (UC) taking ustekinumab (UST). The main question it aims to answer is: Can we de-escalate UST subcutaneous dose either from every 4 weeks (Q4) to every 8 weeks (Q8) or every 8 weeks (Q8) to every 12 weeks (Q12) in CD or UC patients in deep remission without loosing their response? Researchers will follow UST blood levels, inflammation markers and intestinal mucosa integrity and to see if UST dose can be reduced while maintaining clinical remission. Participants will: Change UST dosing from Q4 to Q8 or from Q8 to Q12. Visit the clinic once every 12 weeks for checkups and tests.

Phase 4
Recruiting

MUHC - Montreal General Hospital

Janssen Inc.

Have you considered Trexall clinical trials?

We made a collection of clinical trials featuring Trexall, we think they might fit your search criteria.
Go to Trials
Image of Washington University School of Medicine in St Louis, United States.

Supplemental Imaging for Breast Cancer

25 - 55
Female
St Louis, MO

Recent research has shown that, among women with extremely dense breasts and normal results on mammogram, magnetic resonance imaging (MRI) use has significantly reduced the occurrence of breast cancer that is diagnosed during the time between two regular screening mammograms (also known as interval cancers). The investigators have developed and validated an approach to use the whole mammogram image, develop a mammogram risk score (MRS), and calibrate this to the SEER breast cancer incidence rates for US women. This model (Prognosia Breast) generates an absolute 5-year risk of breast cancer and classifies approximately 5.7% of the population as high risk using the ASCO 3% cut point as used for endocrine therapy to reduce risk. Follow-up generates an incidence of 25.2 cases per 1,000 women per year.

Waitlist Available
Has No Placebo

Washington University School of Medicine

Tabassum Ahmad, M.D.

Have you considered Trexall clinical trials?

We made a collection of clinical trials featuring Trexall, we think they might fit your search criteria.
Go to Trials